Neos Therapeutics at JMP Securities Life Sciences Conference (Replay)
06/21/17 at 9:30 a.m. ET
Corporate ProfileNeos Therapeutics is focused on developing, manufacturing and commercializing branded products utilizing our proprietary extended-release drug delivery technology platform. We have used this technology to develop our three product candidates being investigated for the treatment of attention deficit hyperactivity disorder, or ADHD. Our ADHD product candidates are extended-release, or XR, medications in patient-friendly, orally disintegrating tablets, or ODT, or liquid suspension dosage forms.
- 06/19/17Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
- 06/14/17Neos Therapeutics to Present at the JMP Securities 2017 Life Sciences Conference
- 05/30/17Neos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference
- 05/16/17Neos Therapeutics to Present at 2017 UBS Global Healthcare Conference